KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Charles River Laboratories International (CRL) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Charles River Laboratories International (CRL) over the last 17 years, with Q3 2025 value amounting to 0.45.

  • Charles River Laboratories International's Equity Ratio fell 407.67% to 0.45 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.45, marking a year-over-year decrease of 407.67%. This contributed to the annual value of 0.46 for FY2024, which is 476.6% up from last year.
  • According to the latest figures from Q3 2025, Charles River Laboratories International's Equity Ratio is 0.45, which was down 407.67% from 0.44 recorded in Q2 2025.
  • Charles River Laboratories International's Equity Ratio's 5-year high stood at 0.47 during Q3 2024, with a 5-year trough of 0.34 in Q3 2021.
  • For the 5-year period, Charles River Laboratories International's Equity Ratio averaged around 0.41, with its median value being 0.42 (2023).
  • As far as peak fluctuations go, Charles River Laboratories International's Equity Ratio plummeted by 630.11% in 2021, and later surged by 2204.66% in 2023.
  • Quarter analysis of 5 years shows Charles River Laboratories International's Equity Ratio stood at 0.36 in 2021, then rose by 8.48% to 0.39 in 2022, then rose by 12.11% to 0.44 in 2023, then increased by 4.77% to 0.46 in 2024, then dropped by 1.44% to 0.45 in 2025.
  • Its Equity Ratio was 0.45 in Q3 2025, compared to 0.44 in Q2 2025 and 0.42 in Q1 2025.